Patents by Inventor Camellia W. Adams

Camellia W. Adams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20220002430
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: April 20, 2021
    Publication date: January 6, 2022
    Applicant: Genentech, Inc.
    Inventors: Camellia W. ADAMS, Andrew C. CHAN, Craig W. CROWLEY, Henry B. LOWMAN, Gerald R. NAKAMURA, Leonard G. PRESTA
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20190071511
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: February 26, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Camellia W. ADAMS, Andrew C. CHAN, Craig W. CROWLEY, Henry B. LOWMAN, Gerald R. NAKAMURA, Leonard G. PRESTA
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20170158773
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: July 22, 2016
    Publication date: June 8, 2017
    Inventors: Camellia W. ADAMS, Andrew C. CHAN, Craig W. CROWLEY, Henry B. LOWMAN, Gerald R. NAKAMURA, Leonard G. PRESTA
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20140154242
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: September 17, 2013
    Publication date: June 5, 2014
    Applicant: Genentech, Inc.
    Inventors: Camellia W. ADAMS, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
  • Antibodies to lymphotoxin-alpha
    Patent number: 8642740
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: February 4, 2014
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • Immunoglobulin variants and uses thereof
    Patent number: 8562992
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: October 22, 2013
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
  • Antibodies to lymphotoxin-?
    Patent number: 8541552
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: September 24, 2013
    Assignee: Genetech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • Method of inducing apoptosis using anti-DR5 antibodies
    Patent number: 8409570
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: April 2, 2013
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • ANTIBODIES TO LYMPHOTOXIN-ALPHA
    Publication number: 20130011412
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Application
    Filed: July 6, 2012
    Publication date: January 10, 2013
    Applicant: Genentech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • Antibodies to lymphotoxin-?
    Patent number: 8216807
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: July 10, 2012
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • DR5 ANTIBODIES AND USES THEREOF
    Publication number: 20120087922
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Application
    Filed: September 7, 2011
    Publication date: April 12, 2012
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • Antibodies to Apo-2 receptor polypeptides
    Patent number: 8092799
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: January 10, 2012
    Assignee: Genentech, Inc.
    Inventors: Camellia W Adams, Avi J Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
  • Nucleic acid encoding DR5 antibodies and uses thereof
    Patent number: 8030023
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • DR5 antibodies and articles of manufacture containing same
    Patent number: 8029783
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • Humanized anti-TGF-beta antibodies
    Patent number: 8012482
    Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: September 6, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Napoleone Ferrara, Ellen Filvaroff, Weiguang Mao, Leonard G. Presta, Max L. Tejada
  • ANTIBODIES TO LYMPHOTOXIN-ALPHA
    Publication number: 20110208673
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Application
    Filed: February 11, 2011
    Publication date: August 25, 2011
    Applicant: Genentech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • ANTIBODIES TO LYMPHOTOXIN-ALPHA
    Publication number: 20110150865
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Application
    Filed: February 11, 2011
    Publication date: June 23, 2011
    Applicant: Genentech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • HUMANIZED ANTI-ERBB2 ANTIBODIES AND TREATMENT WITH ANTI-ERBB2 ANTIBODIES
    Publication number: 20110129464
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Application
    Filed: December 16, 2010
    Publication date: June 2, 2011
    Inventors: CAMELLIA W. ADAMS, Leonard G. Presta, Mark Sliwkowski
  • Antibodies to lymphotoxin-alpha
    Patent number: 7923011
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: April 12, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • ANTIBODIES TO APO-2 RECEPTOR POLYPEPTIDES
    Publication number: 20110008354
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: August 19, 2010
    Publication date: January 13, 2011
    Applicant: GENENTECH, INC.
    Inventors: CAMELLIA W. ADAMS, AVI J. ASHKENAZI, ANAN CHUNTHARAPAI, KYUNG JIN KIM